{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aceclidine",
    "query": {
      "condition": "Aceclidine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T10:53:02.288Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05294328",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia",
        "Refractive Errors",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Aceclidine+Brimonidine combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Proprietary Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2022-05-05",
      "completion_date": "2022-09-10",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-07-22T10:53:02.288Z",
      "location_count": 5,
      "location_summary": "Glendale, California • Indianapolis, Indiana • Andover, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05294328"
    },
    {
      "nct_id": "NCT02554396",
      "title": "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "PRX-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "45 Years to 59 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-09",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2017-10-23",
      "last_synced_at": "2026-07-22T10:53:02.288Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02554396"
    },
    {
      "nct_id": "NCT05936489",
      "title": "Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Presbyopia",
        "Refractive Errors",
        "Brimonidine Tartrate",
        "Aceclidine",
        "Ophthalmic Solutions"
      ],
      "interventions": [
        {
          "name": "Aceclidine + Brimonidine",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-06",
      "completion_date": "2023-10-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-07-22T10:53:02.288Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05936489"
    },
    {
      "nct_id": "NCT05431543",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia",
        "Refractive Errors",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Aceclidine+Brimonidine combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle proprietary ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-08-06",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-07-22T10:53:02.288Z",
      "location_count": 5,
      "location_summary": "Chandler, Arizona • Glendale, California • Andover, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05431543"
    }
  ]
}